Advice for Mid-Size Biopharma on Biomanufacturing Challenges and Strategies for Success

| April 6, 2017

article image
Stephen Lam, Senior Vice President, Patheon, talks with BioPharm International about two of the top challenges facing biopharma today ─ demand forecasting and capacity availability ─ and how to leverage flexibility to ensure a successful biomanufacturing strategy.

Spotlight

B. McLaughlin Associates, Inc (BMA)

BMA is a niche CRO that has been providing functional support in the areas of Data Management and Study Management for over 20 years. Our unique size, coupled with extensive therapeutic experience, allow us to consistently provide personalized, flexible services, and help clients reach critical clinical trial goals and timelines.

OTHER ARTICLES

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 2, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | March 2, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 2, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Spotlight

B. McLaughlin Associates, Inc (BMA)

BMA is a niche CRO that has been providing functional support in the areas of Data Management and Study Management for over 20 years. Our unique size, coupled with extensive therapeutic experience, allow us to consistently provide personalized, flexible services, and help clients reach critical clinical trial goals and timelines.

Events